FDA Classifies Worldwide Voluntary Correction Notice on TRUFILL® n-BCA Liquid Embolic System as Class I Recall

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Classifies Worldwide Voluntary Correction Notice on TRUFILL® n-BCA Liquid Embolic System as Class I Recall

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

FDA Classifies Worldwide Voluntary Correction Notice on TRUFILL® n-BCA Liquid Embolic System as Class I Recall

01/22/2014 11:41 AM EST

Codman Neuro announced today that the U.S. Food and Drug Administration (FDA) has classified the recently initiated medical device correction notice related to the TRUFILL® n-BCA Liquid Embolic System as a Class I recall.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420